Zyon Ayni - Updates & news from Code Pharma

Press

Zyon Ayni - ynet

“Patients who received the medicine exhibited significant enhancement” | ynet

Leave a Comment / Press /

Dr. Eynat Finkelshtein, Chief Scientific Officer at Code Pharma, featured on ynet TV to discuss Codivir: “When the Covid-19 appeared, we wanted to explore whether our treatment was also effective against Covid.” “In a matter of hours or days, the patients who received the medicine exhibited significant enhancement. Based on these findings, we already have […]

“Patients who received the medicine exhibited significant enhancement” | ynet Read More »

Zyon Ayni - IssueWire

IsuueWire: Code Pharma Announces a Limited Fundraising Round

Leave a Comment / Press /

According to IssueWire, “Code Pharma plans to launch an Initial Public Offering (IPO) on the NASDAQ and Switzerland’s SIX Swiss Exchange. The company had launched a limited fundraising round for international expert investors, allowing them to acquire its shares at a 20% discount with a minimum of USD 100,000 starting from November 25, 2021. All

IsuueWire: Code Pharma Announces a Limited Fundraising Round Read More »

Zyon Ayni - Yahoo

“Scientific Data Strongly Suggest – Codivir is Effective Against Mutations”

Leave a Comment / Press /

“Scientific data regarding Codivir’s mechanism of action strongly suggest that Codivir is effective against mutations of the Covid virus, including the recently discovered Omicron variant”, said Zyon Ayni, CEO and Founder of Code Pharma on Yahoo Finance. The article’s title is “COVID-19 drug developer Code Pharma announces limited fundraising round for international professional investors and

“Scientific Data Strongly Suggest – Codivir is Effective Against Mutations” Read More »

Zyon Ayni - TradeArabia

“The Company is Preparing for Mass Production of Codivir” | TradaArabia

Leave a Comment / Press /

Zyon Ayni, Founder and CEO of Code Pharma, updated the readers of TradeArabia about the process of their new medication: “Codivir showed great success in clinical trials and already has received emergency approvals in different countries for the treatment of coronavirus patients. Our team at Code Pharma are now initiating a multi-country phase 2 study

“The Company is Preparing for Mass Production of Codivir” | TradaArabia Read More »

Zyon Ayni - Pressat

Zyon Ayni: “From Day One, I Saw the Business and Social Potential”

Leave a Comment / Press /

On the Pressat website, it was reported that the antiviral medication Codivir recently received emergency approval for use in many countries after it was proven to be effective against the disease. Zyon Ayni, Founder and CEO of Code Pharma, said in an interview: “From day one, I saw the business and social potential. I was

Zyon Ayni: “From Day One, I Saw the Business and Social Potential” Read More »

Zyon Ayni - Mid East Information

Codivir Showing Impressive Antiviral Effect – Mid East Information

Leave a Comment / Press /

“They found Codivir showing impressive antiviral effect, both in laboratory conditions and in phase 1 clinical trial in humans”, The website Mid East Information wrote about a new drug by Code Pharma. Code Pharma’s Founder and CEO, Zyon Ayni, quoted in the article: “Codivir showed great success in clinical trials and already has received emergency

Codivir Showing Impressive Antiviral Effect – Mid East Information Read More »

Zyon Ayni - The Jerusalem Post

Zyon Ayni: “The Company is Preparing to Submit Emergency Approval Requests”

Leave a Comment / Press /

Codivir, a medicine used to treat HIV that also has a direct antiviral effect on coronavirus, was featured in an article published in the Jerusalem Post. The goal, according to Zyon Ayni, CEO and founder of Code Pharma, is to complete the study in three to six months and then file for emergency use authorization

Zyon Ayni: “The Company is Preparing to Submit Emergency Approval Requests” Read More »

Zyon Ayni - Taiwan News

Zyon Ayni: Antiviral Drug Codivir | Taiwan News

Leave a Comment / Press /

Codivir, an antiviral drug that has shown to be effective against COVID-19, was featured in a Taiwan News article. The peptide had a direct antiviral effect against SARS-CoV-2, the novel Coronavirus that causes COVID-19, according to Code Pharma. Antiviral activity against SARS-CoV-2 and other RNA viruses was demonstrated in vitro at the British virology research

Zyon Ayni: Antiviral Drug Codivir | Taiwan News Read More »

Accessibility